Indaptus Therapeutics Inc (INDP) Stock Price, Quote & News

Company Profile

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly kno...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 427 2727

Website: indaptusrx.com

Address:

Three Columbus Circle, 15th Floor, New York, United States

aztecb Dec. 3 at 6:18 PM

$INDP is now the right time to suggest Meckler reinvents the accordion pill 😂

1 · Reply

AutoAZTrader Nov. 28 at 5:58 PM

$INDP Has no relation to the market; delisting soon.

0 · Reply

wjmax Nov. 27 at 1:59 PM

$INDP The two presentations point out the possibility on the merger of $INDP with $NWBO. https://nwbio.com/wp-content/uploads/NYAS-Slides-FINAL.pdf https://indaptusrx.com/investors/wp-content/uploads/2025/05/INDP-May-2025.pdf $INDP like $NWBO is one of the most undervalued stock in the market. IMO

0 · Reply

wjmax Nov. 26 at 9:24 PM

$INDP Don't be surprised if there is a merger between$NWBO and $INDP.

1 · Reply

aztecb Nov. 26 at 9:05 PM

$INDP Great work team we did it we called it in at 1.91 and out at 2.26 🤡 This weeks gains at $45263738383.37 😂😂😂😂

1 · Reply

aztecb Nov. 26 at 8:24 PM

$INDP Queue some muppet posting saying they called todays rise 😂

0 · Reply

Biomechanika Nov. 25 at 1:30 PM

$INDP What's next? Initial combo data part 1 was a dissapointment efficacy wise, safety profile seemed okay. And the trial is halted. Cash is basically non existent, I don't know how they plan to finance the company.

1 · Reply

SpudZone Nov. 25 at 1:03 PM

Morning all top watches this am: $RUBI $INDP micro caps. Megacaps: $SNDK $BIDU $BABA

3 · Reply

topstockalerts Nov. 21 at 1:11 PM

Pre Market Top Gainers $NVVE $MNDR $INDP $SLXN $SMX

1 · Reply

Petros_Marinakou Nov. 20 at 6:03 PM

$INDP there is no reason for this thing to drop like a rock! Wow 1.76

0 · Reply

Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit

Nov 12, 2025, 8:30 AM EST - 24 days ago

Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Sep 4, 2025, 4:01 PM EDT - 3 months ago

Indaptus Therapeutics Provides Clinical Update

Sep 2, 2025, 4:05 PM EDT - 3 months ago

Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference

Aug 13, 2025, 8:00 AM EDT - 4 months ago

Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 1, 2025, 8:14 AM EDT - 5 months ago

Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants

Jun 25, 2025, 7:00 AM EDT - 5 months ago

Indaptus Therapeutics Announces Reverse Stock Split

Jun 13, 2025, 8:00 AM EDT - 6 months ago

Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants

Jun 2, 2025, 8:00 AM EDT - 6 months ago

Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

May 14, 2025, 8:00 AM EDT - 7 months ago

Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 8:00 AM EDT - 7 months ago

Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit

Mar 25, 2025, 8:00 AM EDT - 9 months ago

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit

Mar 20, 2025, 8:00 AM EDT - 9 months ago

Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20

Mar 18, 2025, 8:00 AM EDT - 9 months ago

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Mar 13, 2025, 7:30 AM EDT - 9 months ago

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Mar 12, 2025, 4:15 PM EDT - 9 months ago

Registration Is Now Open For Tribe Public's Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025

Mar 4, 2025, 8:00 AM EST - 9 months ago

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

Feb 25, 2025, 8:00 AM EST - 10 months ago

Indaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit

Feb 5, 2025, 8:00 AM EST - 10 months ago

Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20

Jan 8, 2025, 8:00 AM EST - 11 months ago

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

Nov 22, 2024, 8:36 AM EST - 1 year ago

Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

Nov 11, 2024, 8:00 AM EST - 1 year ago

Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology

Nov 7, 2024, 8:00 AM EST - 1 year ago

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

Oct 23, 2024, 8:00 AM EDT - 1 year ago

Indaptus Therapeutics to Present at Two Upcoming Investor Conferences

May 8, 2024, 8:00 AM EDT - 1 year ago

Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 11, 2024, 7:30 AM EDT - 1 year ago

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

Mar 25, 2024, 8:30 AM EDT - 1 year ago

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting

Mar 13, 2024, 7:30 AM EDT - 1 year ago

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Mar 4, 2024, 7:30 AM EST - 1 year ago

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort

Feb 8, 2024, 8:00 AM EST - 1 year ago

Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels

Jan 4, 2024, 8:00 AM EST - 2 years ago

European Patent Office Approves Key Patent for Indaptus Therapeutics' Platform Technology

Nov 6, 2023, 4:01 PM EST - 2 years ago

Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Oct 31, 2023, 9:01 AM EDT - 2 years ago

Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Registration Is Now Open For Tribe Public's Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics' CEO On Friday, September 29, 2023

Sep 6, 2023, 8:05 AM EDT - 2 years ago

Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 14, 2023, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 10, 2023, 8:45 AM EDT - 2 years ago

Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20

Aug 7, 2023, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer

May 11, 2023, 7:00 AM EDT - 2 years ago

Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 9, 2023, 8:00 AM EDT - 2 years ago

Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform

May 1, 2023, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics' Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit

Apr 20, 2023, 4:05 PM EDT - 2 years ago

Indaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023

Apr 19, 2023, 9:28 AM EDT - 2 years ago

UPDATE -- Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Apr 19, 2023, 8:05 AM EDT - 2 years ago

Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Mar 22, 2023, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics to Present at the Investor Summit Conference

Mar 17, 2023, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

Mar 15, 2023, 8:05 AM EDT - 2 years ago

Indaptus Therapeutics to Present Poster on Its Decoy Anti-Tumor Platform at the American Association for Cancer Research Conference 2023

Mar 13, 2023, 8:05 AM EDT - 2 years ago

Indaptus Therapeutics Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Mar 7, 2023, 8:05 AM EST - 2 years ago

Indaptus Therapeutics Doses First Subject in its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Feb 14, 2023, 8:00 AM EST - 3 years ago

Indaptus Therapeutics Names Robert Martell, M.D., Ph.D. to its Board of Directors

aztecb Dec. 3 at 6:18 PM

$INDP is now the right time to suggest Meckler reinvents the accordion pill 😂

1 · Reply

AutoAZTrader Nov. 28 at 5:58 PM

$INDP Has no relation to the market; delisting soon.

0 · Reply

wjmax Nov. 27 at 1:59 PM

0 · Reply

wjmax Nov. 26 at 9:24 PM

$INDP Don't be surprised if there is a merger between$NWBO and $INDP.

1 · Reply

aztecb Nov. 26 at 9:05 PM

$INDP Great work team we did it we called it in at 1.91 and out at 2.26 🤡 This weeks gains at $45263738383.37 😂😂😂😂

1 · Reply

aztecb Nov. 26 at 8:24 PM

$INDP Queue some muppet posting saying they called todays rise 😂

0 · Reply

Biomechanika Nov. 25 at 1:30 PM

1 · Reply

SpudZone Nov. 25 at 1:03 PM

Morning all top watches this am: $RUBI $INDP micro caps. Megacaps: $SNDK $BIDU $BABA

3 · Reply

topstockalerts Nov. 21 at 1:11 PM

Pre Market Top Gainers $NVVE $MNDR $INDP $SLXN $SMX

1 · Reply

Petros_Marinakou Nov. 20 at 6:03 PM

$INDP there is no reason for this thing to drop like a rock! Wow 1.76

0 · Reply

TheStoicOne Nov. 20 at 1:05 PM

$INDP never even realized how bad im loaimg here. Great!

1 · Reply

LabPsycho Nov. 19 at 7:59 PM

$INDP Hmmm...will this be another biotech that pivots to trading digital faux ponzi scheme currencies?

0 · Reply

Remolabarca22 Nov. 19 at 5:05 PM

$INDP next runner soon

1 · Reply

BioTechHealthX Nov. 18 at 4:04 AM

$INDP INDP stock gains attention as Indaptus Therapeutics secures $2.3M through its ATM facility, completes its Safety Lead-In cohort, and posts improving financial trends—positioning the company for a pivotal clinical expansion heading into 2026. https://biotechhealthx.com/biotech-news/why-indaptus-indp-could-be-a-sleeper-biotech-winner-after-2-3m-financing-boost-and-phase-1-progress/

0 · Reply

stockanalysis_ Nov. 17 at 11:34 PM

After Hours Gainers: $NOTV $RYET $MC $KXIN $INDP Bookmark this page: https://stockanalysis.com/markets/afterhours/gainers/?ref=saveontrading

0 · Reply

TwongStocks Nov. 17 at 9:10 PM

$INDP Link to the conference agenda. https://donor-selection-cell-source-summit.com/day-one/ The synopsis of Dr Newman's presentation is very interesting. "Suggesting that GMP Decoy bacteria may represent an ideal treatment to enhance activity and reduce variability during manufacturing of allogeneic cell therapies." They recently paused enrollment in the current Decoy20 trial, pending further efficacy evaluation. I wonder if they plan to pivot Decoy20 development. Instead of testing it in combination with tislelizumab as a cancer treatment, I wonder if they are now considering testing Decoy20 as a means to improve manufacturing of allogenic cell therapies.

0 · Reply

TwongStocks Nov. 17 at 1:03 PM

$INDP Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit https://www.globenewswire.com/news-release/2025/11/17/3189055/0/en/Indaptus-Therapeutics-Chief-Scientific-Officer-Dr-Michael-Newman-to-Present-at-the-Donor-Selection-Cell-Source-Summit.html Dr. Newman stated, “Allogeneic therapies, which rely on donor-derived immune cells to create ‘off-the-shelf’ cancer treatments, face a major hurdle when it comes to achieving consistent potency across donor sources. Our preclinical data show that Decoy bacteria can activate or induce the production of key immune cell types—such as NK cells, gamma-delta T cells, and M1 macrophages—that are also central to the success of allogeneic immunotherapies. This suggests that Decoy bacteria may have potential as an enabling tool to enhance the potency and reproducibility of donor-derived cell therapies.”

0 · Reply

6monthinvester Nov. 15 at 5:45 PM

$INDP good high risk high reward

0 · Reply

ThatDudeWithNoMoney Nov. 13 at 1:14 PM

$THAR $IXHL $PSTV $INDP FDA NEWS!!! OPENING BELL RIPPER!!!

3 · Reply

TwongStocks Nov. 12 at 1:49 PM

$INDP Decoy20 trial paused. "The Safety Review Committee has reviewed all available safety data from this cohort and determined that the Decoy20 and tislelizumab combination appears to be tolerable at the current dose and schedule. While this safety data may support proceeding to full enrollment, we have paused enrollment pending additional efficacy evaluations of the remaining participants and to further assess our next development options."

1 · Reply

TwongStocks Nov. 12 at 1:47 PM

$INDP 10-Q https://www.sec.gov/ix?doc=/Archives/edgar/data/1857044/000149315225021759/form10-q.htm • 1,751,163 share soutstanding as of Nov 11 • Increase in shares from Q2 primarily came from conversion of promissory notes (+501,566 shares) and use of the ATM (+520,000 shares).

0 · Reply

TwongStocks Nov. 12 at 1:35 PM

$INDP Q3 Financial results and corporate update https://www.globenewswire.com/news-release/2025/11/12/3186262/0/en/Indaptus-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html • Completed the Safety Lead-In cohort, dosing six evaluable participants with the combination of Decoy20 and tislelizumab. • July 2025, completed conversion of the promissory notes, that were issued in June 2025 for $5.7 million, into common stock, pre-funded warrants and warrants. • September 2025, strengthened balance sheet with $2.3 million raised through at-the-market facility. • As of September 30, the Company had cash and cash equivalents of approximately $5.8 million. The Company expects that its current cash and cash equivalents will support ongoing operating activities into the first quarter of 2026.

0 · Reply

Market Cap	4.38M
Revenue (ttm)	0.00
Net Income (ttm)	-15.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	86,700
Avg Vol	549,052
Day's Range	N/A - N/A
Shares Out	1.75M
Stochastic %K	100%
Beta	1.02
Analysts	Strong Sell
Price Target	$10.00